200 related articles for article (PubMed ID: 30419253)
21. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
22. Phage Display-Derived Cross-Reactive Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A16.
Zhang X; Sun C; Xiao X; Pang L; Shen S; Zhang J; Cen S; Yang BB; Huang Y; Sheng W; Zeng Y
Jpn J Infect Dis; 2016; 69(1):66-74. PubMed ID: 26073737
[TBL] [Abstract][Full Text] [Related]
23. Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism.
Du R; An C; Yao X; Wang Y; Wang G; Gao F; Bian L; Hu Y; Liu S; Zhao Q; Mao Q; Liang Z
Emerg Microbes Infect; 2023 Dec; 12(1):2149352. PubMed ID: 36395069
[TBL] [Abstract][Full Text] [Related]
24. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants.
Mao QY; Liao XY; Yu X; Li N; Zhu FC; Zeng Y; Liang ZL; Li FX; Wang JZ; Lu FM; Zhuang H
Chin Med J (Engl); 2010 Jul; 123(13):1679-84. PubMed ID: 20819628
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology Characteristics of Human Coxsackievirus A16 and Enterovirus 71 Circulating in Linyi, China, from 2009 to 2017.
Yin DQ; Wang CB; Wang CB; Xiao-Zhou ; Ji SX
Jpn J Infect Dis; 2018 Nov; 71(6):470-473. PubMed ID: 29962487
[TBL] [Abstract][Full Text] [Related]
26. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of putative novel microRNA expression profiles induced by enterovirus 71 and coxsackievirus A16 infections in human umbilical vein endothelial cells using high-throughput sequencing.
Song J; Hu Y; Zheng H; Guo L; Huang X; Jiang X; Li W; Li J; Yang Z; Dong S; Liu L
Infect Genet Evol; 2019 Sep; 73():401-410. PubMed ID: 31176031
[TBL] [Abstract][Full Text] [Related]
28. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine.
Fan S; Liao Y; Jiang G; Jiang L; Wang L; Xu X; Feng M; Yang E; Zhang Y; Cui W; Li Q
Vaccine; 2020 Feb; 38(8):2034-2044. PubMed ID: 31982260
[TBL] [Abstract][Full Text] [Related]
29. Identification and production of mouse scFv to specific epitope of enterovirus-71 virion protein-2 (VP2).
Thanongsaksrikul J; Srimanote P; Tongtawe P; Glab-Ampai K; Malik AA; Supasorn O; Chiawwit P; Poovorawan Y; Chaicumpa W
Arch Virol; 2018 May; 163(5):1141-1152. PubMed ID: 29356992
[TBL] [Abstract][Full Text] [Related]
30. Comparing Enterovirus 71 with Coxsackievirus A16 by analyzing nucleotide sequences and antigenicity of recombinant proteins of VP1s and VP4s.
Li Y; Zhu R; Qian Y; Deng J; Sun Y; Liu L; Wang F; Zhao L
BMC Microbiol; 2011 Nov; 11():246. PubMed ID: 22050722
[TBL] [Abstract][Full Text] [Related]
31. [Preparation of pan-neutralizing mouse monoclonal antibodies against enterovirus 71 and coxsackievirus A16].
Jiang Z; Tian X; Zhang Y; Cheng Q; Lu X; Zhong B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):645-650. PubMed ID: 34140076
[TBL] [Abstract][Full Text] [Related]
32. Coxsackievirus A16: epidemiology, diagnosis, and vaccine.
Mao Q; Wang Y; Yao X; Bian L; Wu X; Xu M; Liang Z
Hum Vaccin Immunother; 2014; 10(2):360-7. PubMed ID: 24231751
[TBL] [Abstract][Full Text] [Related]
33. [Comparisons of epidemiological and clinical characteristics in children with hand-foot-mouth disease caused by Enterovirus 71 and Coxackievirus A16].
Jia L; Zhao CS; Zhang L; Li S; Zhang DT; Liu BW; Wang QY; Li XY
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Aug; 13(8):635-7. PubMed ID: 21849112
[TBL] [Abstract][Full Text] [Related]
34. Chemokine PF4 Inhibits EV71 and CA16 Infections at the Entry Stage.
Pei Z; Wang H; Zhao Z; Chen X; Huan C; Zhang W
J Virol; 2022 Jun; 96(11):e0043522. PubMed ID: 35579435
[TBL] [Abstract][Full Text] [Related]
35. Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity.
Jia Q; Ng Q; Chin W; Meng T; Chow VTK; Wang CI; Kwang J; He F
Sci Rep; 2017 Apr; 7():46402. PubMed ID: 28422137
[TBL] [Abstract][Full Text] [Related]
36. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
Li J; Liu G; Liu X; Yang J; Chang J; Zhang W; Yu XF
Viruses; 2015 Jul; 7(7):3891-909. PubMed ID: 26193302
[TBL] [Abstract][Full Text] [Related]
37. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71.
Deng YQ; Ma J; Xu LJ; Li YX; Zhao H; Han JF; Tao J; Li XF; Zhu SY; Qin ED; Qin CF
Appl Microbiol Biotechnol; 2015 Sep; 99(18):7663-71. PubMed ID: 25967656
[TBL] [Abstract][Full Text] [Related]
38. VP2 dominated CD4+ T cell responses against enterovirus 71 and cross-reactivity against coxsackievirus A16 and polioviruses in a healthy population.
Tan S; Tan X; Sun X; Lu G; Chen CC; Yan J; Liu J; Xu W; Gao GF
J Immunol; 2013 Aug; 191(4):1637-47. PubMed ID: 23863902
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies for diagnosis of enterovirus 71.
Xu L; Huang KJ; Ho TS; Liu CC; Lee YR; Lin CY; Shiuan D; Jiang XH
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):386-94. PubMed ID: 24328741
[TBL] [Abstract][Full Text] [Related]
40. [Mechanism of intravenous immunoglobulin therapy for severe hand-foot-mouth disease: a review].
Cao R; Han J; Qin E; Qin C
Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):712-6. PubMed ID: 21845837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
